Sequence information
Variant position: 1170 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1255 The length of the canonical sequence.
Location on the sequence:
PSPREGPLPAARPAGATLER
P KTLSPGKNGVVKDVFAFGGA
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human PSPREGPLPAARPAGATLERP KTLSP-----GKNGVVKDVFAFGGA
PLALEGPLPPSRPAGATLERP KTLSPKTLSPGKNGVVKDVF
Mouse PLTPEGPPPPIRPAGATLERP KTLSP-----GKNGVVKDVF
Rat PLTPEGPLPPVRPAGATLERP KTLSP-----GKNGVVKDVF
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Literature citations
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.
Coussens L.; Yang-Feng T.L.; Liao Y.C.; Chen E.; Gray A.; McGrath J.; Seeburg P.H.; Libermann T.A.; Schlessinger J.; Francke U.; Levinson A.; Ullrich A.;
Science 230:1132-1139(1985)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1); VARIANT ALA-1170;
Submission
NIEHS SNPs program;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS CYS-452; VAL-655 AND ALA-1170;
Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2) gene.
Sarkar F.H.; Ball D.E.; Li Y.W.; Crissman J.D.;
DNA Cell Biol. 12:611-615(1993)
Cited for: NUCLEOTIDE SEQUENCE OF 1081-1245; VARIANT ALA-1170;
Patterns of somatic mutation in human cancer genomes.
Greenman C.; Stephens P.; Smith R.; Dalgliesh G.L.; Hunter C.; Bignell G.; Davies H.; Teague J.; Butler A.; Stevens C.; Edkins S.; O'Meara S.; Vastrik I.; Schmidt E.E.; Avis T.; Barthorpe S.; Bhamra G.; Buck G.; Choudhury B.; Clements J.; Cole J.; Dicks E.; Forbes S.; Gray K.; Halliday K.; Harrison R.; Hills K.; Hinton J.; Jenkinson A.; Jones D.; Menzies A.; Mironenko T.; Perry J.; Raine K.; Richardson D.; Shepherd R.; Small A.; Tofts C.; Varian J.; Webb T.; West S.; Widaa S.; Yates A.; Cahill D.P.; Louis D.N.; Goldstraw P.; Nicholson A.G.; Brasseur F.; Looijenga L.; Weber B.L.; Chiew Y.-E.; DeFazio A.; Greaves M.F.; Green A.R.; Campbell P.; Birney E.; Easton D.F.; Chenevix-Trench G.; Tan M.-H.; Khoo S.K.; Teh B.T.; Yuen S.T.; Leung S.Y.; Wooster R.; Futreal P.A.; Stratton M.R.;
Nature 446:153-158(2007)
Cited for: VARIANTS [LARGE SCALE ANALYSIS] VAL-654; VAL-655; SER-768; ALA-1170 AND ASP-1216; VARIANT GASC SER-776; VARIANT OC SER-857;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.